Stock ENTX ENTERA BIO LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Entera Bio Ltd.

Equities

ENTX

IL0011429839

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-26 EDT 		5-day change 1st Jan Change
1.98 USD -1.00% Intraday chart for Entera Bio Ltd. -0.50% +230.00%
04-08 Entera Bio Ltd. Announces Publication of Oral PTH(1-34) Peptide Tablets Phase 2 Trial Data in the Journal of Bone and Mineral Research CI
03-26 Entera Bio Ltd. Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs Is Expected Within 10 Months CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Entera Bio Ltd. Announces Publication of Oral PTH(1-34) Peptide Tablets Phase 2 Trial Data in the Journal of Bone and Mineral Research
Entera Bio Ltd. Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs Is Expected Within 10 Months
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
Entera Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Top Premarket Gainers
Top Premarket Gainers
Entera Bio Ltd. Announces Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform
Entera Bio Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Entera Bio Ltd. Reports Key Milestone Relating to Oral PTH (1-34) Peptide Phase 3 Program
Entera Bio Ltd. Reports Rapid Pharmacodynamic (Pd) Response and Consistent Pharmacokinetic (Pk) Data for Its First-In-Class Oral Pth(1-34) Mini Tablets At the Asbmr 2023 Annual Meeting
Entera Bio Ltd. Announces Collaboration with OPKO Biologics, Inc. to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes
Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research Annual Meeting
Entera Bio Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Entera Bio Ltd Adds Haya Taitel to its Board of Directors
Entera Bio Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Entera Bio Ltd.'S Oral Delivery of GLP-2 Pre-Clinical Data to Be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics
Steven R. Goldstein Joins Entera Bio Ltd.'s Clinical and Scientific Advisory Board
Entera Bio Ltd. Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program
Entera Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
Entera Bio Ltd. Auditor Raises 'Going Concern' Doubt
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ENTX Stock
  4. News Entera Bio Ltd.
  5. Other languages